Search Results - "Dronamraju, Nalina"

P517: SURVIVAL OUTCOMES WITH CPX‐351 VS 7 + 3 BY BASELINE BONE MARROW BLAST PERCENTAGE IN OLDER ADULTS WITH NEWLY DIAGNOSED HIGH‐RISK OR SECONDARY ACUTE MYELOID LEUKEMIA: A 5‐YEAR FOLLOW‐UP STUDY by Ritchie, Ellen, L. Lin, Tara, F. Newell, Laura, K. Stuart, Robert, Solomon, Scott, Stone, Richard, Schiller, Gary, Wieduwilt, Matthew, Amy Ryan, Eileen, Dronamraju, Nalina, Lancet, Jeffrey, Cortes, Jorge

Get full text

P516: CARDIOTOXICITY OF CPX‐351 VS 7 + 3 IN PATIENTS WITH UNTREATED HIGH‐RISK ACUTE MYELOID LEUKEMIA by Mitchell, Joshua D., Pfeiffer, Michael, Boehmer, John, Gorcsan, John, Dronamraju, Nalina, Faderl, Stefan, L. Lin, Tara, L. Uy, Geoffrey, Lancet, Jeffrey, Cortes, Jorge

Get full text

Effect of Intensive Urate Lowering With Combined Verinurad and Febuxostat on Albuminuria in Patients With Type 2 Diabetes: A Randomized Trial by Stack, Austin G., Dronamraju, Nalina, Parkinson, Joanna, Johansson, Susanne, Johnsson, Eva, Erlandsson, Fredrik, Terkeltaub, Robert

“…Hyperuricemia has been implicated in the development and progression of chronic kidney disease. Verinurad is a novel, potent, specific urate reabsorption…”
Get full text

0391 Physician Perspective on Idiopathic Hypersomnia: Awareness, Diagnosis, and Impact on Patients by Whalen, Marisa, Roy, Bailey, Steininger, Teresa, Dronamraju, Nalina, Enson, Daniel

Get full text

0392 Patient Perspective on Idiopathic Hypersomnia: Impact on Quality of Life and Satisfaction With the Diagnostic Process and Management by Whalen, Marisa, Roy, Bailey, Steininger, Teresa, Dronamraju, Nalina, Enson, Daniel

Get full text

0762 Baseline characteristics: Solriamfetol’s effect on cognitive Health in Apnea participants during a Randomized Placebo-controlled study (SHARP) by Van Dongen, Hans, Dronamraju, Nalina, Macfadden, Wayne, Leary, Eileen

Get full text

Mavoglurant in Parkinson's patients with l-Dopa-induced dyskinesias: Two randomized phase 2 studies by Trenkwalder, Claudia, Stocchi, Fabrizio, Poewe, Werner, Dronamraju, Nalina, Kenney, Chris, Shah, Amy, von Raison, Florian, Graf, Ana

“…ABSTRACT Background Two phase 2 randomized, double‐blind studies were designed to evaluate efficacy and safety of immediate‐release (study 1) and…”
Get full text

Dapagliflozin Added to Verinurad Plus Febuxostat Further Reduces Serum Uric Acid in Hyperuricemia: The QUARTZ Study by Stack, Austin G, Han, David, Goldwater, Ronald, Johansson, Susanne, Dronamraju, Nalina, Oscarsson, Jan, Johnsson, Eva, Parkinson, Joanna, Erlandsson, Fredrik

“…Abstract Context Combining a sodium-glucose cotransporter 2 inhibitor with a xanthine oxidase inhibitor (XOI) and a urate transporter 1 (URAT1) inhibitor may…”
Get full text

Resolution of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) with Defibrotide Following HCT in Adult and Pediatric Patients: Pooled Analysis of Defifrance and EBMT PASS Registries by Mohty, Mohamad, Locatelli, Franco, Blaise, Didier, Peffault De Latour, Regis, Labussière-Wallet, Hélène, Amber, Vian, Gandemer, Virginie, Gutierrez, Deborah, Dronamraju, Nalina, Dalle, Jean-Hugues, Srour, Micha

“…Introduction Veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) is a potentially life-threatening complication of hematopoietic cell…”
Get full text

Cardiotoxicity of CPX-351 vs 7+3 in patients with untreated high-risk acute myeloid leukemia by Mitchell, Joshua, Pfeiffer, Michael, Boehmer, John, Gorcsan, John, Dronamraju, Nalina, Faderl, Stefan, Lin, Tara L., Uy, Geoffrey L., Lancet, Jeffrey E., Cortes, Jorge E.

“…7029 Background: CPX-351, a dual-drug liposomal encapsulation of daunorubicin and cytarabine in a synergistic 1:5 molar ratio, is approved for newly diagnosed,…”
Get full text

Outcomes of Defibrotide-Treated Patients with Anicteric/Icteric Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) after Hematopoietic Cell Transplantation (HCT): Results from the Defifrance Registry Study by Gandemer, Virginie, Guenounou, Sarah, Legrand, Faezeh, Blaise, Didier, Peffault de Latour, Régis, Duchêne, François, Dronamraju, Nalina, Yakoub-Agha, Ibrahim, Labopin, Myriam, Dalle, Jean-Hugues, Mohty, Mohamad

Get full text

Survival outcomes with CPX-351 vs 7+3 by baseline bone marrow blast percentage in older adults with newly diagnosed high-risk or secondary acute myeloid leukemia: A 5-year follow-up study by Ritchie, Ellen K., Lin, Tara L., Newell, Laura F., Stuart, Robert K., Solomon, Scott R., Stone, Richard M., Schiller, Gary J., Wieduwilt, Matthew Joseph, Ryan, Eileen A., Dronamraju, Nalina, Lancet, Jeffrey E., Cortes, Jorge E.

“…7027 Background: CPX-351, a dual-drug liposomal encapsulation of daunorubicin and cytarabine in a synergistic 1:5 molar ratio, is approved for newly diagnosed…”
Get full text

Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add‐on to metformin in patients with type 2 diabetes by Müller‐Wieland, Dirk, Kellerer, Monika, Cypryk, Katarzyna, Skripova, Dasa, Rohwedder, Katja, Johnsson, Eva, Garcia‐Sanchez, Ricardo, Kurlyandskaya, Raisa, Sjöström, C. David, Jacob, Stephan, Seufert, Jochen, Dronamraju, Nalina, Csomós, Katalin

“…Objective To compare the efficacy and safety of dapagliflozin and dapagliflozin plus saxagliptin vs glimepiride as add‐on to metformin in patients with type 2…”
Get full text

Efficacy and safety of dapagliflozin plus saxagliptin versus insulin glargine over 52weeks as add‐on to metformin with or without sulphonylurea in patients with type 2 diabetes: A randomized, parallel‐design, open‐label, Phase 3 trial by Vilsbøll, Tina, Ekholm, Ella, Johnsson, Eva, Ricardo Garcia‐Sanchez, Dronamraju, Nalina, Jabbour, Serge A, Lind, Marcus

“…AimEfficacy and safety of dapagliflozin plus saxagliptin (DAPA + SAXA) were compared with insulin glargine (INS) in patients with type 2 diabetes (T2D) in a…”
Get full text

Dapagliflozin plus saxagliptin add‐on to metformin reduces liver fat and adipose tissue volume in patients with type 2 diabetes by Johansson, Lars, Hockings, Paul D., Johnsson, Eva, Dronamraju, Nalina, Maaske, Jill, Garcia‐Sanchez, Ricardo, Wilding, John P. H.

“…Aim To assess the effects of dapagliflozin plus saxagliptin plus metformin versus glimepiride plus metformin on liver fat (proton density fat fraction) and…”
Get full text

SP262THE IMPACT OF URATE-LOWERING DRUGS VERINURAD AND FEBUXOSTAT ON ALBUMINURIA IN TYPE 2 DIABETES by Stack, Austin, Dronamraju, Nalina, Parkinson, Joanna, Johansson, Susanne, Johnsson, Eva, Erlandsson, Fredrik, Terkeltaub, Robert

Get full text

Treatment Duration, Symptom Resolution, and Survival in Defibrotide-Treated Patients with Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation: Pooled Analysis of Defifrance and EBMT PASS Registries by Mohty, Mohamad, Locatelli, Franco, Blaise, Didier, Peffault de Latour, Régis, Labopin, Myriam, Labussière-Wallet, Hélène, Amber, Vian, Gandemer, Virginie, Gutierrez, Deborah, Dronamraju, Nalina, Dalle, Jean-Hugues, Yakoub-Agha, Ibrahim

Get full text

Dapagliflozin Plus Saxagliptin Add-on Therapy Compared With Insulin in Patients With Type 2 Diabetes Poorly Controlled by Metformin With or Without Sulfonylurea Therapy: A Randomized Clinical Trial by Vilsbøll, Tina, Ekholm, Ella, Johnsson, Eva, Dronamraju, Nalina, Jabbour, Serge, Lind, Marcus

“…This study evaluated whether an oral combination of a sodium-glucose cotransporter 2 inhibitor and a dipeptidyl peptidase 4 inhibitor achieved glycemic control…”
Get full text

Dapagliflozin plus Saxagliptin Shows Noninferior A1C Reduction vs. Insulin Glargine in Patients with Type 2 Diabetes Inadequately Controlled by Metformin With or Without Sulfonylurea by VILSBØLL, TINA, EKHOLM, ELLA, JOHNSSON, EVA K., DRONAMRAJU, NALINA, JABBOUR, SERGE, LIND, MARCUS

“…This international, multicenter, randomized, open-label phase 3b trial (NCT02551874) evaluated the efficacy and safety of dapagliflozin (DAPA) 10 mg/day plus…”
Get full text

Cover Image, Volume 22, Issue 7 by Johansson, Lars, Hockings, Paul D., Johnsson, Eva, Dronamraju, Nalina, Maaske, Jill, Garcia‐Sanchez, Ricardo, Wilding, John P. H.

Get full text